Actively Recruiting
Edaravone in the Treatment of Optic Neuritis
Led by First Affiliated Hospital of Guangxi Medical University · Updated on 2025-02-27
50
Participants Needed
1
Research Sites
206 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.
CONDITIONS
Official Title
Edaravone in the Treatment of Optic Neuritis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Chinese patients aged 18 years or older with anti-aquaporin-4 antibody-positive optic neuritis
- Patients experiencing their first episode of optic neuritis in either eye
- First symptoms of optic neuritis started within 30 days before edaravone treatment
You will not qualify if you...
- Myopia greater than 6 diopters
- Opacity in the eye's refractive media that affects retinal or visual acuity assessment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yi Du
Nanning, China, 530021
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here